FibroBiologics (NASDAQ:FBLG) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $7.00 target price on the stock.

FBLG has been the subject of several other reports. HC Wainwright reduced their price target on FibroBiologics to $4.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, FibroBiologics presently has an average rating of “Hold” and an average target price of $5.50.

FibroBiologics Price Performance

NASDAQ:FBLG opened at $0.34 on Thursday. FibroBiologics has a one year low of $0.22 and a one year high of $1.53. The company has a market cap of $22.99 million, a P/E ratio of -0.81 and a beta of -0.69. The firm’s fifty day moving average price is $0.31 and its two-hundred day moving average price is $0.38.

FibroBiologics (NASDAQ:FBLG) last posted its earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.06. As a group, equities research analysts expect that FibroBiologics will post -0.53 earnings per share for the current year.

Insider Transactions at FibroBiologics

In other FibroBiologics news, CFO Jason Davis bought 70,000 shares of the stock in a transaction on Monday, March 2nd. The stock was purchased at an average price of $0.41 per share, with a total value of $28,700.00. Following the completion of the purchase, the chief financial officer owned 70,000 shares in the company, valued at $28,700. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders bought a total of 191,500 shares of company stock valued at $72,893 in the last quarter. Insiders own 13.00% of the company’s stock.

Institutional Investors Weigh In On FibroBiologics

Several hedge funds and other institutional investors have recently made changes to their positions in FBLG. Yorkville Advisors Global LP bought a new position in FibroBiologics in the 3rd quarter valued at approximately $278,000. Landscape Capital Management L.L.C. bought a new stake in shares of FibroBiologics during the third quarter worth $191,000. Geode Capital Management LLC increased its holdings in shares of FibroBiologics by 20.7% during the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after buying an additional 59,813 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of FibroBiologics by 287.3% during the fourth quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock worth $52,000 after buying an additional 171,800 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of FibroBiologics in the 4th quarter valued at $34,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.